NIH will partner drug industry to study Alzheimer’s, diabetes, and autoimmune disordersBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1397 (Published 06 February 2014) Cite this as: BMJ 2014;348:g1397
- Michael McCarthy
The US National Institutes of Health (NIH) will partner 10 biopharmaceutical companies to identify promising drug targets and disease biomarkers, the agency announced on 4 February. Eight nonprofit organizations will also participate in the collaboration.
The initiative, called the Accelerating Medicines Partnership, will initially focus on biomarkers and drug targets for Alzheimer’s disease, type 2 diabetes, and the autoimmune disorders of rheumatoid arthritis and systemic erythematosus.
All data and analyses generated by the initiative will be made publicly available “to the broad biomedical community,” the NIH said.
In a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial